🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseLiver biopsy changes on semaglutide — 72-week histology data

Liver biopsy changes on semaglutide — 72-week histology data

MASHdoc_SA Sat, Jun 6, 2026 at 9:47 AM 15 replies 325 viewsPage 1 of 3
MASHdoc_SA
Member
456
2,345
Aug 2024
San Antonio, TX
Jun 6, 2026 at 9:47 AM#1

This gets cited here weekly, usually second-hand, so it is worth setting out what it does and does not establish.

The mechanism that matters here is not stomach emptying, it is central. GLP-1 receptor agonism in the arcuate nucleus stimulates POMC neurons and suppresses AgRP/NPY signalling, which is why the effect is appetite and food salience rather than physical fullness. Delayed gastric emptying largely tachyphylaxes over the first months; the appetite effect does not.

Where I think it is weakest: the population was selected and supported in ways a real cohort is not, so I would read the effect size as a ceiling rather than an expectation.

What I am after is what the dose-response curve actually looks like above 1.7mg, because the trial means hide how few people account for the extra loss. Tell me what I have not thought of.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
1 21TirzTom
Reply Quote Save Share Report
amsterdam_pete
Senior Member
1,567
6,789
Feb 2024
Netherlands
Jun 6, 2026 at 9:57 AM#2
MASHdoc_SA said:
The mechanism that matters here is not stomach emptying, it is central.

All true, with one condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.

50 20ZaraB_AL, JakeSmashed95, NauseaFreeNow and 47 others
Reply Quote Save Share Report
mike.trainer_LA
Senior Member
1,567
7,234
Apr 2024
Los Angeles, CA
Jun 6, 2026 at 10:08 AM#3
MASHdoc_SA said:
The mechanism that matters here is not stomach emptying, it is central.

I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.

Last edited: Jun 6, 2026 at 2:08 PM
49 19mia_MS2, LeilaHI, marcus_mpls and 46 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
paige_pharma
Member
289
1,234
Sep 2024
Omaha, NE
Jun 6, 2026 at 10:18 AM#4

This one has a reasonably settled answer, so here it is. Albumin binding above 99% is the whole reason weekly dosing works, and it is also why the trough matters more than the peak. People who dose late are not losing a peak, they are letting the trough fall, and the appetite effect tracks the trough.

48 18lisa_labSD, adam_van, Dr.SurgeonPGH and 45 others
Reply Quote Save Share Report
JenPlateau
Member
234
890
Nov 2024
Missouri
Jun 6, 2026 at 11:16 AM#5
amsterdam_pete said:
All true, with one condition: that curve is for people who reached the dose on schedule.

That holds for the injectable. The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people quote them as if they were.

47 17sarah_nash92, FitDadDave, RunnerRach and 44 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register